#GLP1 Read the full story here

Be alert to dizziness when changing positions Monitor blood pressure if possible, as dehydration can cause drops Note frequency and colour of urination throughout the day Medical considerations Adjust medication timing to minimise side effects that contribute to dehydration Consider temporary dose adjustment in consultation with your healthcare provider Discuss anti-nausea or anti-diarrhoeal medications if these symptoms are contributing to fluid loss Consider IV fluids for severe cases (requires medical intervention) When to seek medical advice Contact your healthcare provider immediately if you experience: Severe thirst that cannot be satisfied by drinking Little or no urination for 8 hours or more Dizziness or lightheadedness that impairs functioning Confusion, disorientation, or extreme fatigue Rapid heart rate or breathing Fainting or severe weakness Inability to keep fluids down due to vomiting Long-term outlook With proper management, most patients can maintain adequate hydration whilst on GLP-1 treatments

Who Should Be Cautious or Avoid It Growth hormone peptides are generally not appropriate during pregnancy, for people with active or recent cancer (because growth signaling and cell growth are linked), or where there are certain pituitary or metabolic conditions
However, GLP-1s accounted for over 8% of all Medicaid prescription drug spending before rebates in 2024 (up from 1% in 2019)
Thinner needles generally cause less pain, and the short length (typically 4-6 mm) is sufficient for subcutaneous delivery without reaching deeper, more sensitive tissues